Elpiscience Raises $105 Million for Cancer Immunotherapy Portfolio

Elpiscience Biopharma, a Shanghai cancer immunotherapy company, closed a $105 million Series C round to start US trials of its innovative portfolio. The company also plans to research novel mechanisms for cancer immunotherapy and support additional partnerships. Elpiscience has built a pipeline of 15 innovative molecules, including three candidates in clinical trials and three in-house developed molecules at the IND-enabling stage. The company says its candidates must have a differentiated biology that shows efficacy in a clinical setting platform. The C round was led by the Greater Bay Area Homeland Development Fund. More details.... Share this with colleagues: // //